NCT02564198 2021-08-17
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
8 trialsNCT02999295 2019-08-21
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
National Cancer Center, Japan
Phase 1/2 Completed
NCT01285037 2018-02-20
A Study of LY2801653 in Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01017731 2015-06-10
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
Eli Lilly and Company
Phase 2 Completed
NCT00627042 2014-10-08
Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy
Eli Lilly and Company
Phase 2 Completed
NCT01246960 2014-10-08
A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00786383 2013-08-19
Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy
Eli Lilly and Company
Phase 1 Completed
NCT00793975 2013-08-19
Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy
Eli Lilly and Company
Phase 1 Completed